NBY
NovaBay Pharmaceuticals Inc
NYSE MKT: NBY · HEALTHCARE · BIOTECHNOLOGY
$1.95
+22.64% today
Updated 2026-04-02
Market cap
$51.92M
P/E ratio
—
P/S ratio
0.16x
EPS (TTM)
$-28.50
Dividend yield
—
52W range
$1 – $100
Volume
1.3M
WallStSmart proprietary scores
40
out of 100
Grade: D
Sell
Investment rating
3.7
Growth
D4.5
Quality
C4.5
Profitability
C6.7
Valuation
B1/9
Piotroski F-Score
Weak
-82.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$0.85
-56.41%
12-Month target
—
—
Intrinsic (DCF)
$1.66
Margin of safety
+60.12%
Price chart
X-Ray snapshot
Strengths
+ 60.12% below intrinsic value
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -82.66 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-2.27M
- Revenue declining -78.70% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $14.40M | $10.46M | $9.78M | $0.00 | $10.30M |
| Net income | $-10.61M | $-9.64M | $-7.22M | $-22.14M | $-26.60M |
| EPS | — | — | — | — | $-28.50 |
| Free cash flow | $-6.77M | $-4.28M | $-5.19M | $-8.43M | $-2.27M |
| Profit margin | -73.65% | -92.20% | -73.85% | — | — |
Peer comparison
Smart narrative
NovaBay Pharmaceuticals Inc trades at $1.95. Our Smart Value Score of 40/100 indicates the stock is fair. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -82.66, it sits in the distress. TTM revenue stands at $10.30M. Our DCF model estimates intrinsic value at $1.66.
Frequently asked questions
What is NovaBay Pharmaceuticals Inc's stock price?
NovaBay Pharmaceuticals Inc (NBY) trades at $1.95.
Is NovaBay Pharmaceuticals Inc overvalued?
Smart Value Score 40/100 (Grade D, Sell). DCF value $1.66.
What is the price target of NovaBay Pharmaceuticals Inc (NBY)?
The analyst target price is $0.85, representing -56.4% downside from the current price of $1.95.
What is the intrinsic value of NovaBay Pharmaceuticals Inc (NBY)?
Based on our DCF model, intrinsic value is $1.66, a +60.1% margin of safety versus $1.95.
What is NovaBay Pharmaceuticals Inc's revenue?
TTM revenue is $10.30M.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
-82.66 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE MKT
CurrencyUSD
Quick metrics
P/S ratio0.16x
ROE-516.00%
Beta0.16
50D MA$3.53
200D MA$9.62
Shares out0.03B
Float0.00B
Short ratio—
Avg volume1.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—